Clinical Trial Update: A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial of ASTX727 (oral decitabine/cedazuridine) for hematologic neoplasms after allogeneic stem cell transplantation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Neoplasms

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Allogeneic Stem Cell Transplantation | Phase 2 | Status: WITHDRAWN